Interesting CLS Put And Call Options For March 27th

Celestica (CLS) is trading at $293.45. Selling the $280 put (bid $26.50) would obligate purchase at $280 but nets a cost basis of $253.50 and is ~5% OTM with a 59% chance to expire worthless, equating to a 9.46% cash return or 69.15% annualized YieldBoost. Selling a $295 covered call (bid $32.00) against shares bought at $293.45 would produce an 11.43% total return if called to the March 27 expiration, is ~1% OTM with a 47% chance to expire worthless and a 10.90% premium boost (79.67% annualized). Implied volatilities are 76% for the put and 87% for the call versus a trailing-12m volatility of 74%.

Analysis

Market structure: These option quotes create a winner set comprised of short-premium, income-oriented investors and prospective long buyers who prefer a lower effective entry (cash‑secured put at $280 nets $253.50). Sellers benefit from elevated IV (76–87%) vs realized 74% that keeps premium rich; directional longs risk being called away or assigned. Cross-asset: a short-term spike in equity vol would pressure credit spreads for cyclical EMS suppliers and create modest CAD/USD sensitivity for CLS revenue recognition.

Risk assessment: Near-term (to March 27) probabilities are explicit — ~59% for 280 put expiring worthless and ~47% for 295 call — so time-decay favors premium sellers within weeks. Tail risks: major customer order cuts, semiconductor downturn, export controls or large FX moves could drop shares >15–30% quickly. Hidden deps include customer concentration and inventory destocking; catalysts to watch: quarterly earnings, order-book commentary, global electronics PMIs within 30–90 days.

Trade implications: Direct, quantifiable plays are attractive: cash‑secured 280 put (net entry $253.50) or buy at $293.45 and sell 295 covered call (collect $32) to lock ~11.4% to March. If preferring defined risk, sell 280/250 put spread or 295/315 call spread to capture skew while capping loss. Pair ideas: long CLS vs short FLEX (FLEX) 1:1 notional to express company-specific recovery while hedging sector risk.

Contrarian angles: The market may be understating downside risk if macro PMI or a major customer guide lowers orders — premium sellers may be overexposed to a >20% gap. Conversely, IV is only modestly above realized, so volatility compression post-earnings could rapidly favor sellers; historical EMS episodes show sharp IV mean reversion within 2–6 weeks after guidance clarity. Unintended consequence: aggressive put-selling can force concentrated ownership if assigned into a weakening cycle.

Key Decisions for Investors

• Sell cash‑secured CLS Mar 27 280 put at ~$26.50 (effective buy $253.50). Size 1–3% portfolio notional, reserve $280/share, set hard stop/roll if CLS < $240 or IV > 110 to limit tail loss.
• Buy CLS up to $293.45 and sell Mar 27 295 covered call for $32 to collect ~11.4% to expiry. Position size 1–2% portfolio, take profits if stock >295 (let be called) or cut to 50% if price <265 and earnings outlook deteriorates.
• If preferring defined risk, sell 280/250 cash‑secured put spread (receive premium, max loss ~$20 – premium). Target trade if raw put premium >$18; risk per share capped at ~$2, roll/exit if IV jumps +25 vols or stock gaps >10%.
• Construct pair trade: long CLS / short FLEX (FLEX) equal dollar for 2% net exposure to capture idiosyncratic recovery. Rebalance if relative performance diverges >8% or if CLS order book is downgraded.
• Trigger-based monitoring: unwind short premium within 5 trading days if IV compresses >20 vol points or if realized 10-day vol <50; escalate hedges (buy 1x 295 call) if CLS gaps >+12% pre-market.